Showing results (61-70 of 296) with videos related to
Sort By:
Pageof 30
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 28, 2020
Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trialsJulien Péron, Anouk Neven, Laurence Collette, et al.Plos One|December 20, 2012
Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agentsChristophe Le Tourneau, Hui K Gan, Albiruni R A Razak, et al.Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|March 4, 2011
BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001)Andrea Wittig, Sien-Yi Sheu-Grabellus, Laurence Collette, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca PharmaceuticalsLaurence Collette, Tomasz Burzykowski, Kevin J Carroll, et al.European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trialsXavier Paoletti, Birgit Geoerger, François Doz, et al.Journal of Clinical Microbiology|June 8, 2007
Shelf life of predosed plates containing mefloquine, artemisinin, dihydroartemisinin, and artesunate as used for in vitro Plasmodium falciparum susceptibility assessmentSandrine Houzé, Aline Munier, Xavier Paoletti, et al.BMC Medical Research Methodology|October 5, 2022
The case against censoring of progression-free survival in cancer clinical trials - A pandemic shutdown as an illustrationCorinne Jamoul, Laurence Collette, Elisabeth Coart, et al.Urologic Oncology|October 6, 2014
Long-term follow-up of TaG1 non-muscle-invasive bladder cancerPierre Olivier Bosset, Yann Neuzillet, Xavier Paoletti, et al.Eclinicalmedicine|November 8, 2021
Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysisCamille Moreau Bachelard, Elodie Coquan, Pauline du Rusquec, et al.JAMA Network Open|May 17, 2021
Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical TrialsMartin T King, Ming-Hui Chen, Laurence Collette, et al.Pageof 30